Johnson & Johnson Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent
Johnson & Johnson (JNJ) reported Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent of 0.00% for the 12-month period ending 2018-12-30, per its 10-K filed 2019-02-20.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities · last filed 2019-02-20
- Johnson & Johnson effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2018 was 0.00%, a 100.00% decline from fiscal 2017.
- Johnson & Johnson effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2017 was 0.80%, a 33.33% increase from fiscal 2017.
- Johnson & Johnson effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2017 was 0.60%, a 0.00% change from fiscal 2016.
- Johnson & Johnson effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2016 was 0.60%, a 0.00% change from fiscal 2014.
| Period end | Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent 12 month | Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent 12 month as first filed |
|---|---|---|
| 2018-12-30 | 0.00% 10-K · filed 2019-02-20 | |
| 2017-12-31 | 0.80% 10-K · filed 2019-02-20 | |
| 2017-01-01 | 0.60% 10-K · filed 2019-02-20 | |
| 2016-01-03 | 0.60% 10-K · filed 2018-02-21 | -0.60% 10-K · filed 2016-02-24 |
| 2014-12-28 | 0.60% 10-K · filed 2017-02-27 | -0.60% 10-K · filed 2015-02-24 |
| 2013-12-29 | -0.80% 10-K · filed 2016-02-24 | |
| 2012-12-30 | -0.90% 10-K · filed 2015-02-24 | |
| 2012-01-01 | -0.80% 10-K · filed 2014-02-21 | |
| 2011-01-02 | -0.50% 10-K · filed 2013-02-22 | |
| 2010-01-03 | -0.40% 10-K · filed 2012-02-23 | |
| 2008-12-28 | -0.40% 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |